Minneapolis Nurse Loses DEA Wings: Can't Prescribe Controlled Drugs
Published Date: 9/11/2026
Notice
Summary
Emran Mohammad, a nurse practitioner from Minneapolis, lost his DEA registration because he no longer has state permission to handle controlled substances. The DEA tried hard to contact him but couldn’t reach him, so they decided it’s best for public safety to revoke his registration. This means he can’t legally prescribe or handle controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Named APRN
The Drug Enforcement Administration revoked DEA Certificate of Registration No. MM8483024 issued to Emran Mohammad, RN, APRN, CNP, and denied any pending application to renew or modify that registration as well as any other pending application for additional registration in Minnesota. The Order is effective October 13, 2026.
State License Suspension Bars DEA Registration
The Order reiterates that under 21 U.S.C. 824(a)(3) and related provisions, a registrant who lacks state authority to handle controlled substances (for example because a state nursing or APRN license is suspended) is not eligible to maintain a DEA registration and that lack of state authority is an independent basis for revocation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-18604, Joseph John Stubbers III, D.O.; Decision and Order
Dr. Joseph John Stubbers III from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in Ohio. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of February 28, 2026. This means he can’t legally prescribe or manage controlled drugs anymore, impacting his medical practice and patients.
Next: 2026-18606, Notice of Availability of Final Environmental Assessment and Finding of No Significant Impact
The Department of Defense gave the green light for building a new metal smelting and refining plant in Montgomery County, Tennessee, after checking that it won’t harm the environment. This means Crucible Metals, LLC can get financial help to start the project soon, with support from local and federal agencies. The project promises new jobs and infrastructure without big environmental risks, so things are moving ahead confidently!